Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro

Immunol Today. 1991 Nov;12(11):404-10. doi: 10.1016/0167-5699(91)90142-G.


Clinical and experimental evidence suggests that shock, arthritis, osteoporosis, colitis, leukemia, diabetes, wasting and atherosclerosis are mediated, in part, by interleukin 1 (IL-1). Inhibition of this cytokine has been a strategy for studying disease and for new drug development. A naturally-occurring IL-1 inhibitor (IL-1 receptor antagonist, IL-1ra) that blocks binding of IL-1 to its receptors has been cloned and produced in recombinant organisms. IL-1ra reduces the severity of sepsis, colitis, arthritis and diabetes in animals and is presently being tested in humans with arthritis, shock and myelogenous leukemia.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Arthritis / immunology
  • Disease Models, Animal
  • Humans
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1 / antagonists & inhibitors*
  • Leukemia, Myeloid / immunology
  • Proteins / immunology*
  • Receptors, Immunologic / immunology
  • Receptors, Interleukin-1
  • Recombinant Proteins / immunology
  • Shock / immunology
  • Sialoglycoproteins*


  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Proteins
  • Receptors, Immunologic
  • Receptors, Interleukin-1
  • Recombinant Proteins
  • Sialoglycoproteins